Event Type: The document is a transcript of the Q2 and H1 FY27 Earnings Conference Call, which included a management presentation followed by a question-and-answer session with analysts.
Date and Time: The earnings call was conducted on October 27, 2026. A specific start time was not disclosed in the provided transcript.
Purpose: The stated purpose was to discuss the "key business and financial highlights for the quarter and for the first half of the financial year" ended September 30, 2026. The call was held after the board meeting where the unaudited results were approved.
Management Participants: The following management representatives participated in the call:
Mr. Neeraj Sharma – Chief Executive Officer and Managing Director
Mr. Anurag Bhagania – Chief Financial Officer
Mr. Abhishek Singhal (role not specified, likely Head of Investor Relations)
Availability of Materials: The company confirmed that the earnings "results release and investor presentation" were available on the company's and stock exchange websites. The transcript for the call was scheduled to be posted on the company's website "within the next week" from the call date (October 27, 2026).
UPSI Statement: The document includes standard forward-looking statement language: "today's discussion will contain forward-looking statements, which should be viewed in the context of the risks inherent in our business." There is no explicit statement that no Unpublished Price Sensitive Information (UPSI) would be shared.
Financial Period Discussed: The call focused on the results for Q2 FY27 (quarter ended September 30, 2026) and the first half (H1) of FY27.
Forward-Looking Statements & Strategic Themes: Management provided a strategic update and reaffirmed long-term guidance:
Financial Performance: Q2 FY27 revenue grew 37% YoY and 15% QoQ to over INR 5 billion. EBITDA grew 53% YoY and 32% QoQ, with margins expanding over 400 basis points QoQ to 32%.
Capacity Expansion: The second Drug Device Combination (DDC) cartridge line became operational in September 2026, immediately doubling sterile production days. The third DDC line has completed its factory acceptance test in Germany and is on site for qualification; its commercialization may be pushed to the start of FY28.
Business Segments: The biologics division secured new project wins from a U.S. biotech and a global animal health company. The semaglutide (GLP-1) business saw Hikma launch a generic in Saudi Arabia, and Dr. Reddy's API supply has commenced, enabling a re-launch in Canada and other markets.
Guidance: Management reaffirmed its FY28 outlook of $400 million in revenue and $160 million in EBITDA. They expect H2 FY27 to be stronger than H1 and see growth sustaining beyond FY28 driven by DDC, biologics, and base business expansions.
Additional Notes Section
The document is a regulatory filing submitted pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, containing the full transcript of the earnings call.
Financial Data: The announcement itself contained summarized financial figures (revenue growth of 37% YoY, EBITDA growth of 53% YoY, margin of 32%) and operational metrics. Detailed financial statements were referenced as being available on the company's website.
The transcript includes detailed Q&A with analysts covering topics such as capacity utilization, the impact of geopolitical issues on supply chains and working capital, tax rates, and growth projections beyond FY28.
